核医学診断の世界市場レポート 2025年

核医学診断の市場規模は今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は12.1％で、125億6,000万米ドルに成長します。予測期間の成長は、神経学におけるアプリケーションの拡大、他の画像モダリティとの統合、精密医療へのアプローチ、セラノスティクスの需要の高まり、疾病撲滅への世界の取り組みに起因しています。予測期間の主な動向には、小規模分散型放射線薬局へのシフト、神経学における核医学の応用、ラジオミクスと定量画像解析、研究開発のための共同研究、放射線安全性と線量測定の重視などがあります。

核医学診断市場の成長が期待される背景には、こうした診断技術に対する需要の高まりがあります。核医学は体内の放射性物質を利用して病気を診断したり、治療中に病気や損傷を受けた臓器や組織を狙い撃ちして除去したりします。核医学診断の主な用途は放射線治療やその他の救命治療です。このような診断の需要が増加しているのは、正確な結果や治療の意思決定能力の向上などの利点があるためです。原子力発電を提唱する英国の国際組織である世界原子力協会が2022年4月に報告したように、核医学治療の年間件数は4,000万件を超え、放射性同位元素の需要は毎年最大5％の成長率を示しています。特筆すべきは、医療における放射性同位元素を含む処置の90％以上が、世界中の1万以上の病院で実施されていることです。この需要の急増は、核医学診断の極めて重要な役割を強調し、核医学診断市場の予想成長に貢献しています。

がん罹患率の増加が、今後数年間の核医学診断市場の成長を牽引すると予測されています。がんは、腫瘍の形成につながる異常な細胞の無秩序な増殖と拡散を特徴とする疾患の集合体を指します。核医学診断は、特殊なカメラで識別可能な放射性物質を使用し、臓器や組織の内部構造や機能の詳細な画像を生成することで、様々な種類のがんの検出、病期分類、モニタリングにおいて重要な役割を果たしています。例えば、2023年1月、米国の政府間機関である国立生物工学情報センター（National Center for Biotechnology Information）は、その年の米国における新たながん患者数は195万8310人、がんに関連する死亡者数は60万9820人であったと報告しました。このように、がん患者数の増加が核医学診断市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界核医学診断 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の核医学診断市場：成長率分析
• 世界の核医学診断市場の実績：規模と成長, 2019-2024
• 世界の核医学診断市場の予測：規模と成長, 2024-2029, 2034F
• 世界核医学診断総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の核医学診断市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• SPECT放射性医薬品
• PET放射性医薬品
• 世界の核医学診断市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心臓病学
• 甲状腺
• 神経学
• 腫瘍学
• その他の用途
• 世界の核医学診断市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診断センター
• 調査機関
• 世界の核医学診断市場SPECT放射性医薬品の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• テクネチウム99mベースの放射性医薬品
• ヨウ素123ベースの放射性医薬品
• タリウム201ベースの放射性医薬品
• その他のSPECT放射性医薬品
• 世界の核医学診断市場PET放射性医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フッ素18系放射性医薬品
• 炭素11ベースの放射性医薬品
• ガリウム68ベースの放射性医薬品
• その他のPET放射性医薬品

第7章 地域別・国別分析

• 世界の核医学診断市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の核医学診断市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 核医学診断市場：競合情勢
• 核医学診断市場：企業プロファイル
  • Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GE Healthcare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Perkin Elmer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Mallinckrodt Pharmaceuticals
• Bracco Diagnostics Inc.
• Lantheus Holdings Inc.
• IBA Radiopharma Solutions
• Curium SAS
• Cardinal Health Inc.
• Eckert & Ziegler Strahlen-und Medizintechnik AG
• Advanced Accelerator Applications
• Telix Pharmaceuticals Limited
• Nordion（Canada）Inc.
• NorthStar Medical Technologies LLC
• SHINE Medical Technologies LLC
• Navidea Biopharmaceuticals Inc.
• Cyclopharm Limited
• Isologic Innovative Radiopharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 核医学診断市場2029：新たな機会を提供する国
• 核医学診断市場2029：新たな機会を提供するセグメント
• 核医学診断市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Nuclear medicine employs radioactive substances administered internally to diagnose illnesses or selectively target and eliminate diseased or damaged organs and tissues during treatment. This field encompasses the utilization of radioactive drugs for research, therapeutic, and diagnostic objectives. In diagnostic nuclear medicine, radioactive tracers are employed to visualize and/or measure the overall or localized function of specific organs, providing valuable insights for medical diagnosis and treatment planning.

The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.

The nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $7.16 billion in 2024 to $7.94 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to advancements in medical imaging, increasing prevalence of chronic diseases, aging population trends, clinical applications in oncology, diagnostic accuracy and precision.

The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $12.56 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to expanding applications in neurology, integration with other imaging modalities, precision medicine approaches, rising demand for theranostics, global efforts in disease eradication. Major trends in the forecast period include shift towards small-scale, decentralized radiopharmacy, application of nuclear medicine in neurology, radiomics and quantitative imaging analysis, collaborations for research and development, emphasis on radiation safety and dosimetry.

The anticipated growth of the nuclear medicine diagnostics market is driven by a rising demand for these diagnostic techniques. Nuclear medicine utilizes radioactive substances within the body for diagnosing illnesses and for targeted removal of diseased or damaged organs and tissues during treatment. The applications of nuclear medicine diagnostics are predominantly in radiation and other life-saving treatments. The increasing demand for these diagnostics is attributed to their advantages, including accurate results and enhanced treatment decision-making capabilities. As reported in April 2022 by the World Nuclear Association, a UK-based international organization advocating for nuclear power, the annual number of nuclear medicine treatments surpasses 40 million, with the demand for radioisotopes witnessing a yearly growth rate of up to 5%. Notably, over 90% of procedures involving radioisotopes in medicine are conducted in more than 10,000 hospitals worldwide. This surge in demand underscores the pivotal role of nuclear medicine diagnostics, contributing to the anticipated growth of the nuclear medicine diagnostics market.

The increasing incidence of cancer is anticipated to drive the growth of the nuclear medicine diagnostics market in the coming years. Cancer refers to a collection of diseases characterized by the uncontrolled proliferation and spread of abnormal cells, which can lead to the formation of tumors. Nuclear medicine diagnostics plays a crucial role in detecting, staging, and monitoring various cancer types by using radioactive substances that can be identified by specialized cameras, producing detailed images of the internal structures and functions of organs and tissues. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported that there were 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States that year. Thus, the rising number of cancer cases is fueling the expansion of the nuclear medicine diagnostics market.

Prominent companies in the nuclear medicine diagnostics market are strategically focusing on the introduction of advanced solutions, particularly advanced medical technologies, to establish a competitive advantage. Advanced medical technologies represent cutting-edge innovations within the medical field, aimed at improving patient outcomes, elevating the standard of care, and fostering overall health improvement. An illustrative example is Gleneagles Hospital, a Malaysia-based company providing medical and healthcare services. In August 2023, the hospital introduced a Nuclear Medicine Unit, showcasing its commitment to advanced medical technologies. This specialized unit, equipped with state-of-the-art technology and staffed by highly skilled professionals, is designed to facilitate early detection, diagnosis, and treatment of diseases through nuclear medicine imaging techniques. Such initiatives by major companies underscore the industry's dedication to advancing technology and enhancing medical capabilities within the nuclear medicine diagnostics market.

Major companies in the nuclear medicine diagnostics market are actively pursuing strategic partnerships as a key approach to securing a competitive edge. Strategic partnerships involve collaborative efforts between two or more entities with the goal of achieving mutually advantageous objectives by combining resources and expertise. A noteworthy example occurred in June 2023, where RLS Inc., a US-based nuclear medicine provider, entered into a strategic partnership with SOFIE, a US-based molecular imaging company. Through this collaboration, RLS Inc. aims to enhance the distribution of nuclear medicine doses to patients, hospitals, teaching institutions, and doctors, thereby improving the overall continuum of care for patients. This strategic partnership will streamline patient dose preparation, capitalizing on the accredited radiopharmacy network and expertise of both entities involved. Such initiatives underscore the industry's commitment to fostering collaboration and leveraging collective strengths to drive advancements in the nuclear medicine diagnostics market.

In January 2022, Eckert & Ziegler, a Germany-based provider of isotope technology for medical, scientific, and industrial applications, successfully acquired Tecnonuclear SA for an undisclosed sum. This strategic acquisition positions Eckert & Ziegler to broaden its footprint and enhance essential healthcare services in Brazil and across South America. Tecnonuclear SA, an Argentina-based specialist in nuclear medicine, brings valuable expertise and resources to strengthen Eckert & Ziegler's presence in the region, aligning with the company's commitment to advancing isotope technology for medical applications.

Major companies operating in the nuclear medicine diagnostics market include Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Cardinal Health Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Global Medical Solutions LLC, Theragnostics Ltd., EczacIbasI-Monrol Nuclear Products Co.

North America was the largest region in the nuclear medicine diagnostics market in 2024. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: SPECT Radiopharmaceuticals; PET Radiopharmaceuticals
• 2) By Application: Cardiology; Thyroid; Neurology; Oncology; Other Applications
• 3) By End-User: Hospitals And Diagnostic Centers; Research Institutes
• Subsegments:
• 1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals; Iodine-123-Based Radiopharmaceuticals; Thallium-201-Based Radiopharmaceuticals; Other SPECT Radiopharmaceuticals
• 2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals; Carbon-11-Based Radiopharmaceuticals; Gallium-68-Based Radiopharmaceuticals; Other PET Radiopharmaceuticals
• Companies Mentioned: Siemens AG; Bayer Aktiengesellschaft; Novartis AG; GE Healthcare Technologies Inc.; Perkin Elmer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nuclear Medicine Diagnostics Market Characteristics

3. Nuclear Medicine Diagnostics Market Trends And Strategies

4. Nuclear Medicine Diagnostics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Nuclear Medicine Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nuclear Medicine Diagnostics Market Growth Rate Analysis
• 5.4. Global Nuclear Medicine Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nuclear Medicine Diagnostics Total Addressable Market (TAM)

6. Nuclear Medicine Diagnostics Market Segmentation

• 6.1. Global Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SPECT Radiopharmaceuticals
• PET Radiopharmaceuticals
• 6.2. Global Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiology
• Thyroid
• Neurology
• Oncology
• Other Applications
• 6.3. Global Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Diagnostic Centers
• Research Institutes
• 6.4. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of SPECT Radiopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Technetium-99m-Based Radiopharmaceuticals
• Iodine-123-Based Radiopharmaceuticals
• Thallium-201-Based Radiopharmaceuticals
• Other SPECT Radiopharmaceuticals
• 6.5. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of PET Radiopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluorine-18-Based Radiopharmaceuticals
• Carbon-11-Based Radiopharmaceuticals
• Gallium-68-Based Radiopharmaceuticals
• Other PET Radiopharmaceuticals

7. Nuclear Medicine Diagnostics Market Regional And Country Analysis

• 7.1. Global Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nuclear Medicine Diagnostics Market

• 8.1. Asia-Pacific Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nuclear Medicine Diagnostics Market

• 9.1. China Nuclear Medicine Diagnostics Market Overview
• 9.2. China Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nuclear Medicine Diagnostics Market

• 10.1. India Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nuclear Medicine Diagnostics Market

• 11.1. Japan Nuclear Medicine Diagnostics Market Overview
• 11.2. Japan Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nuclear Medicine Diagnostics Market

• 12.1. Australia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nuclear Medicine Diagnostics Market

• 13.1. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nuclear Medicine Diagnostics Market

• 14.1. South Korea Nuclear Medicine Diagnostics Market Overview
• 14.2. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nuclear Medicine Diagnostics Market

• 15.1. Western Europe Nuclear Medicine Diagnostics Market Overview
• 15.2. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nuclear Medicine Diagnostics Market

• 16.1. UK Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nuclear Medicine Diagnostics Market

• 17.1. Germany Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nuclear Medicine Diagnostics Market

• 18.1. France Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nuclear Medicine Diagnostics Market

• 19.1. Italy Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nuclear Medicine Diagnostics Market

• 20.1. Spain Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nuclear Medicine Diagnostics Market

• 21.1. Eastern Europe Nuclear Medicine Diagnostics Market Overview
• 21.2. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nuclear Medicine Diagnostics Market

• 22.1. Russia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nuclear Medicine Diagnostics Market

• 23.1. North America Nuclear Medicine Diagnostics Market Overview
• 23.2. North America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nuclear Medicine Diagnostics Market

• 24.1. USA Nuclear Medicine Diagnostics Market Overview
• 24.2. USA Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nuclear Medicine Diagnostics Market

• 25.1. Canada Nuclear Medicine Diagnostics Market Overview
• 25.2. Canada Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nuclear Medicine Diagnostics Market

• 26.1. South America Nuclear Medicine Diagnostics Market Overview
• 26.2. South America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nuclear Medicine Diagnostics Market

• 27.1. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nuclear Medicine Diagnostics Market

• 28.1. Middle East Nuclear Medicine Diagnostics Market Overview
• 28.2. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nuclear Medicine Diagnostics Market

• 29.1. Africa Nuclear Medicine Diagnostics Market Overview
• 29.2. Africa Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Nuclear Medicine Diagnostics Market Competitive Landscape
• 30.2. Nuclear Medicine Diagnostics Market Company Profiles
  • 30.2.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GE Healthcare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Perkin Elmer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

• 31.1. Mallinckrodt Pharmaceuticals
• 31.2. Bracco Diagnostics Inc.
• 31.3. Lantheus Holdings Inc.
• 31.4. IBA Radiopharma Solutions
• 31.5. Curium SAS
• 31.6. Cardinal Health Inc.
• 31.7. Eckert & Ziegler Strahlen- und Medizintechnik AG
• 31.8. Advanced Accelerator Applications
• 31.9. Telix Pharmaceuticals Limited
• 31.10. Nordion (Canada) Inc.
• 31.11. NorthStar Medical Technologies LLC
• 31.12. SHINE Medical Technologies LLC
• 31.13. Navidea Biopharmaceuticals Inc.
• 31.14. Cyclopharm Limited
• 31.15. Isologic Innovative Radiopharmaceuticals

32. Global Nuclear Medicine Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market

34. Recent Developments In The Nuclear Medicine Diagnostics Market

35. Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Nuclear Medicine Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nuclear Medicine Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nuclear Medicine Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer